fda warning letters compounded semaglutide tirzepatide september 2025 Beyond the Headlines: to GLP-1 Compounders FDA Warns 30 Telehealth Companies

Even in states with coverage, prior authorization requirements are often more stringent than commercial insurance

Focus on foods that are less likely to cause fermentation and bloating, such as lean proteins, non-starchy vegetables, and healthy fats, while temporarily reducing high-fiber foods, carbonated beverages, and artificial sweeteners

Your energy and metabolism depend on adequate B12 status, particularly during the first 6 months of treatment when your body is adjusting to appetite changes

Similarly, symptoms such as fever, jaundice (yellowing of the skin/eyes), or pain in the right upper abdomen could indicate gallbladder problems, which are also associated with GLP-1 receptor agonists

This review will discuss the limitation of GLP1RAs in patients with HF, along with ongoing trials assessing the safety and effectiveness of tirzepatide, look into the existing data, and elucidate tirzepatides potential impact on cardiovascular disease